

# Contents

<b>Foreword</b>	<b>xiii</b>
<b>Preface</b>	<b>xvii</b>
<b>Contributors</b>	<b>xix</b>
<b>Acknowledgments</b>	<b>xxv</b>
<b>1 Introduction</b>	<b>1</b>
<i>Thomas P. Gross</i>	
<b>2 Medical device regulation in the USA</b>	<b>5</b>
<i>Thomas P. Gross, Celia M. Witten, and Casper Uldriks</i>	
Introduction	5
Premarket review	6
Marketing applications	8
Postmarket oversight	10
Conclusion	18
<b>3 Medical device epidemiology</b>	<b>21</b>
<i>Roselie A. Bright and S. Lori Brown</i>	
Introduction	21
Features of medical devices that are relevant to epidemiology study design	26
Study designs for medical device epidemiology	35
Summary and recommendations	37
<b>4 Surveillance of adverse medical device events</b>	<b>43</b>
<i>Roselie A. Bright</i>	
Introduction	43
Rationale for surveillance	44
Surveillance based on adverse event reports	47
Surveillance based on registries	52
Active surveillance	53
Necessary conditions for effective surveillance	54
Ideal AMDE surveillance program	55
Summary	58

<b>5</b>	<b>The Medical Product Surveillance Network (MedSun)</b>	<b>63</b>
	<i>Roselie A. Bright, Marilyn N. Flack, and Susan N. Gardner</i>	
	Historical motivation	63
	Initial considerations for the design of DeviceNet	64
	MedSun basic design	69
	Current status	71
	Is MedSun successful in promoting the safe use of medical devices?	74
	Epidemiologic considerations	75
	Summary	76
<b>6</b>	<b>The National Electronic Injury Surveillance System (NEISS) and medical devices</b>	<b>79</b>
	<i>Brockton J. Hefflin, Thomas P. Gross, and Thomas J. Schroeder</i>	
	Description and history of NEISS	79
	Potential uses and limitations of NEISS	80
	Utilization of NEISS to produce national medical device-associated adverse event estimates	81
	Potential for long-term utilization of NEISS for medical device surveillance	83
<b>7</b>	<b>Medical device nomenclature</b>	<b>87</b>
	<i>Brockton J. Hefflin, Thomas P. Gross, Elizabeth A. Richardson, and Vivian H. Coates</i>	
	Technical elements	87
	Current terminologies	91
	Applications of nomenclature	93
	Future developments	95
<b>8</b>	<b>Data sources for medical device epidemiology studies and data mining</b>	<b>99</b>
	<i>Danica Marinac-Dabic, Baoguang Wang, Brockton J. Hefflin, Heshu J. Duggirala, Tripti M. Mathew, and Cara J. Krulewitch</i>	
	Introduction	99
	Data sources	100
	Surveillance databases	101
	Registries	105
	Automated large administrative databases	112
	National surveys	115
	Data mining	119
	Future use databases for medical device epidemiology	120
<b>9</b>	<b>Ethical requirements and guidelines for epidemiological studies of medical devices</b>	<b>127</b>
	<i>Danica Marinac-Dabic and Suzanne C. Fitzpatrick</i>	
	Introduction	127
	Bioethics foundations	128

US government human subjects protection regulations	128
HHS human subjects protection regulatory requirements	130
FDA human subjects protection regulations	131
Other professional ethical guidelines	133
Ethical requirements for medical devices epidemiologic studies	136
Future ethical requirements for epidemiologic studies	142
<b>10 An industry perspective: medical device epidemiology and surveillance</b>	<b>145</b>
<i>Martha A. Feldman</i>	
Introduction	145
The product's life cycle: premarket (preclinical and clinical) and postmarket (PM) studies	148
Postmarket studies	153
Summary	156
<b>11 Perspective from an academic on postmarket surveillance</b>	<b>159</b>
<i>Lazar J. Greenfield</i>	
Introduction	159
Adverse event reporting	160
Postmarket condition of approval studies and Section 522 studies	163
Industry use of information from adverse event reports	165
Academic opportunities	167
Summary	168
<b>12 Perspective from a pharmacoepidemiologist</b>	<b>171</b>
<i>Thomas K. Hazlet</i>	
Introduction	171
Review of literature	171
Contrasts with pharmacoepidemiology	173
Conclusions	175
<b>13 Medical device regulation and surveillance: perspective from the EU</b>	<b>177</b>
<i>Lennart Philipson</i>	
Introduction	177
Medical devices: the European directives and definitions	178
New approach	179
Classification of medical devices in Europe	182
Market surveillance	183
Traceability of medical devices in Europe	184
The vigilance system	184
<b>14 A consumer advocate's perspective on medical device epidemiology and surveillance</b>	<b>187</b>
<i>Diana M. Zuckerman</i>	
Examples of widely publicized problems with selected medical devices	189
Consumer concerns	193

Regulatory mechanism recommendations	197
Consumer group accomplishments: mixed results	199
<b>15 Pediatric Medical Device Use</b>	<b>203</b>
<i>Judith U. Cope and Thomas P. Gross</i>	
Introduction	203
Medical device use in children	204
Special device risks and safety concerns for children	211
Regulatory framework	212
The future for pediatric medical device surveillance and epidemiology	214
<b>16 Selected medical devices used to manage diabetes mellitus</b>	<b>219</b>
<i>Shewit Bezabeh, Joy H. Samuels-Reid, and Dale R. Tavis</i>	
Introduction	219
Insulin delivery devices	221
Continuous glucose monitoring devices	225
Future medical devices for the management of diabetes	228
<b>17 Medical device-related outbreaks</b>	<b>237</b>
<i>S. Lori Brown, Heshu J. Duggirala, and Dale R. Tavis</i>	
Introduction	237
Endoscopes: bronchoscopes and gastrointestinal (GI) endoscopes	239
Hemodialysis-related outbreaks	244
Neonatal and pediatric intensive care units	247
Miscellaneous device-related outbreaks	250
Summary	251
<b>18 Risk of transmission of prions with medical devices</b>	<b>259</b>
<i>S. Lori Brown and Azadeh Shoaibi</i>	
Iatrogenic transmission of prion disease via neurological or surgical instruments	260
Surgical instruments used to transplant tissues known to have transmitted prion disease (corneal transplant)	261
Surgical instruments in contact with lower risk peripheral tissues	262
Decontaminating surgical instruments to reduce risk of TSE transmission	263
FDA measures to minimize risk of transmission of BSE by medical products	267
Summary	268
<b>19 Surveillance and epidemiology as tools for evaluating the materials used in medical devices</b>	<b>273</b>
<i>Roselie A. Bright</i>	
Introduction	273
General considerations that affect the design of epidemiologic studies of materials used in medical devices	273
Example: natural rubber and latex allergy	279
Summary	286

<b>20 Exploring methods for analyzing surveillance reports on electromagnetic interference with medical devices</b>	<b>291</b>
<i>S. Lori Brown, Nilsa Loyo-Berrios, Michèle G. Bonhomme, Donald M. Witters, Nancy A. Pressly, and Jeffrey L. Silberberg</i>	
Electromagnetic interference with medical devices	292
The MAUDE database	292
Adverse event reports to FDA (December 1984–October 1995): EMI with cardiovascular devices	293
Adverse events reported to FDA (January 1994–March 2005): a recent epidemiological analysis	297
Discussion	311
<b>21 Alternative and complementary medical devices</b>	<b>319</b>
<i>S. Lori Brown and Joannie C. Shen</i>	
Introduction	319
Acupuncture needles	322
Ear candles	326
Magnets	328
Adverse events associated with alternative or complementary devices	331
<b>22 Drug-eluting coronary stents</b>	<b>335</b>
<i>Hesha J. Duggirala, Thomas P. Gross, and David E. Kandzari</i>	
History and evolution of coronary stents: clinical perspective	335
Novel drug-eluting stent programs	340
Comparative trials of drug-eluting stents	342
Application of drug-eluting stents in complex coronary lesion subsets	345
Drug-eluting stents: regulatory perspective	346
<b>23 The treatment of abdominal aortic aneurysms</b>	<b>355</b>
<i>Dale R. Tavriss and Louis M. Messina</i>	
Natural history and indications for treatment	355
FDA experience with the postmarket assessment of an endovascular graft	358
Advances in stent-graft design and performance	361
Conclusion	363
<b>24 Cardiovascular devices: aortic valves</b>	<b>367</b>
<i>Ronald G. Kaczmarek and Chih-Hsin K. Liu</i>	
Introduction	367
Operative mortality	370
The FDA guidance for replacement valves and the objective performance criteria (OPC)	372
Adverse event reports	373
The need for epidemiological studies	373
Conclusions	376
<b>25 Hemostasis Devices</b>	<b>379</b>
<i>Dale R. Tavriss, Beverly Gallauresi, and Ralph G. Brindis</i>	
The ideal vascular hemostasis device	380
Origin of FDA concern with the postmarket performance of hemostasis devices	382

FDA study to evaluate the risk associated with hemostasis device use	387
Possible reasons for FDA findings of apparent protective effects of hemostasis devices	389
Follow-up FDA study to assess the safety of hemostasis devices	389
Conclusion	390
<b>26 ENT devices: cochlear implants</b>	<b>395</b>
<i>James K. Kane and Eric A. Mann</i>	
Cochlear implant description	395
Epidemiological investigations involving meningitis associated with cochlear implants	396
Conclusions	405
<b>27 Silicone gel-filled breast implants: surveillance and epidemiology</b>	<b>407</b>
<i>S. Lori Brown and Joan Ferlo Todd</i>	
Breast implant types	407
A brief regulatory history of breast implants	409
FDA surveillance studies on breast implants	411
Summary	421
<b>28 Ophthalmic devices and clinical epidemiology</b>	<b>427</b>
<i>Malvina B. Eydelman, Gene Hilmantel, James Saviola, and Don Calogero</i>	
Introduction	427
Epidemiological contributions to IOL evaluation	427
Epidemiology of contact lens ulcers and public policy	430
Conclusion	437
<b>29 Orthopedic devices: epidemiologic considerations</b>	<b>441</b>
<i>Ronald G. Kaczmarek, Michele G. Bonhomme, Stanley A. Brown, Judith U. Cope, and Daniel S. McGunagle</i>	
Introduction	441
Selected orthopedic materials	441
Artificial hips	444
Intervertebral disc replacement	452
Data sources and selected methodological issues to consider in epidemiologic studies of orthopedic medical devices	456
Summary	458
<b>30 Clinical epidemiology of intrapartum fetal monitoring devices</b>	<b>463</b>
<i>Danica Marinac-Dabic, Barry S. Schifrin, Cara J. Krulewitch, and Roscoe M. Moore</i>	
Introduction	463
Electronic fetal monitoring	464
Scalp and umbilical cord blood gases analyses	470
Fetal pulse oximetry	471
Fetal ECG waveform monitoring	473
Challenges of intrapartum fetal monitoring modalities	476
Conclusion	478

<b>31 The postmarket surveillance of medical devices: meeting the challenge</b>	<b>483</b>
<i>Susan N. Gardner and Daniel Schultz</i>	
<b>Index</b>	<b>487</b>

